Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 1.22B -6.9% |
| Revenue (ttm) | 252.25M +223.7% |
| Net Income | -220.77M |
| EPS | -2.51 |
| Shares Out | 89.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,626,197 |
| Open | 13.58 |
| Previous Close | 13.53 |
| Day's Range | 13.43 - 14.05 |
| 52-Week Range | 12.99 - 25.59 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 37.27 (+173.04%) |
| Est. Earnings | Nov 2, 2026 |
About SNDX
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination... [Read more]
Financial Performance
In 2025, Syndax Pharmaceuticals's revenue was $172.35 million, an increase of 627.84% compared to the previous year's $23.68 million. Losses were -$285.42 million, -10.46% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $37.27, which is an increase of 173.04% from the latest price.
News
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (r...
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investor...
Syndax valuation unchanged after trial miss, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Syndax (SNDX) with a $38 price target after the Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed the endpoint. “While disappointing,…
Syndax selloff brings attractive entry point, says Citi
Citi views the selloff in Syndax (SNDX) shares after the Phase 2 study of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint as creating an attractive entry point. Citi…
Syndax price target lowered to $23 from $26 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on Syndax (SNDX) to $23 from $26 and keeps a Buy rating on the shares after the company announced MAXPIRe, its…
Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint
Syndax (SNDX) Pharmaceuticals announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced…
Syndax says idiopathic pulmonary fibrosis study did not meet endpoint
16:02 EDT Syndax (SNDX) says idiopathic pulmonary fibrosis study did not meet endpoint
Syndax to end development of axatilimab in idiopathic pulmonary fibrosis
16:03 EDT Syndax (SNDX) to end development of axatilimab in idiopathic pulmonary fibrosis
Syndax sinks 15% to $14 after idiopathic pulmonary fibrosis miss
16:03 EDT Syndax (SNDX) sinks 15% to $14 after idiopathic pulmonary fibrosis miss
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axati...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1...
Syndax Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two commercial assets are generating strong revenue, with Revuforj and Niktimvo both exceeding $200 million annually. Real-world data show evolving AML treatment practices, and multiple pivotal studies and pipeline assets are advancing, with key phase II readouts expected in Q4.
Syndax Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
Strong commercial momentum continues with 85%+ AML market share and robust revenue growth. Multiple pivotal and innovative studies are advancing in AML, IPF, and GVHD, with key data readouts expected by year-end. Early-stage assets in EGFR-mutant lung cancer and myelofibrosis expand the pipeline.
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying abo...
Syndax price target lowered to $33 from $37 at UBS
UBS analyst David Dai lowered the firm’s price target on Syndax (SNDX) to $33 from $37 and keeps a Buy rating on the shares.
Syndax price target lowered to $40 from $44 at JPMorgan
JPMorgan analyst Anupam Rama lowered the firm’s price target on Syndax (SNDX) to $40 from $44 and keeps an Overweight rating on the shares.
Syndax price target lowered to $38 from $40 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Syndax (SNDX) to $38 from $40 and keeps a Buy rating on the shares. The firm says the company delivered another solid…
Syndax Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, with Revuforj and Niktimvo annualizing above $200M each and total revenue up 92% year-over-year. Revuforj's market leadership in menin inhibition and Niktimvo's expanding adoption in chronic GVHD drive confidence in multi-billion-dollar peak sales potential.
Syndax Pharmaceuticals Earnings release: Q2 2026
Syndax Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Syndax Pharmaceuticals Quarterly report: Q2 2026
Syndax Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Syndax Pharmaceuticals Slides: Q2 2026
Syndax Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net...
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo...
Syndax Pharmaceuticals Transcript: R&D Day 2026
The company is advancing a robust pipeline with late-stage and next-gen assets in leukemia, GVHD, IPF, myelofibrosis, and EGFR-mutant NSCLC. Multiple pivotal trials and IND filings are expected through 2027, supported by strong financials and strategic collaborations.